Variables All (n=524) DAPT (n=220) ACT (n=304) P-value
Major peri-procedural complications Major peri-procedural complications Major peri-procedural complications Major peri-procedural complications Major peri-procedural complications
Death, immediate peri-procedural (any), n (%) 0 (0.0) 0 (0.0) 0 (0.0) >0.99
Need for cardio-pulmonary resuscitation, n (%) 3 (0.6) 3 (1.4) 0 (0.0) 0.07
Pericardial effusion requiring intervention, n (%) 5 (1.0) 2 (0.9) 3 (1.0) >0.99
Stroke (any), n (%) 2 (0.4) 0 (0.0) 2 (0.7) 0.51
Major bleeding (≥BARC 3a), n (%) 5 (1.0) 2 (0.9) 3 (1.0) >0.99
Need for bailout surgery, n (%) 0 (0.0) 0 (0.0) 0 (0.0) >0.99
Device embolization, n (%) 2 (0.4) 1 (0.5) 1 (0.3) >0.99
Acute echocardiographic outcomes Acute echocardiographic outcomes Acute echocardiographic outcomes Acute echocardiographic outcomes Acute echocardiographic outcomes
Residual flow, n (%) 8 (1.5) 3 (1.4) 5 (1.6) >0.99
Significant flow, n (%) 0 (0.0) 0 (0.0) 0 (0.0) >0.99
DRT, n (%) 1 (0.2) 0 (0.0) 1 (0.3) >0.99
Anti-thrombotic medical therapy post LAAC Anti-thrombotic medical therapy post LAAC Anti-thrombotic medical therapy post LAAC Anti-thrombotic medical therapy post LAAC Anti-thrombotic medical therapy post LAAC
Any oral anticoagulation, n (%) 270 (51.5) 0 (0.0) 34 (11.2) <0.01
Vitamin K antagonists, n (%) 259 (49.4) 0 (0.0) 23 (7.6) <0.01
Non-vitamin K antagonists, n (%) 11 (2.1) 0 (0.0) 11 (3.6) <0.01
Low molecular weight heparin, n (%) 34 (6.5) 0 (0.0) 270 (88.8) <0.01
Aspirin, n (%) 524 (100.0) 220 (100.0) 304 (100.0) >0.99
Platelet inhibitors other than aspirin, n (%) 220 (42.0) 220 (100.0) 0 (0.0) <0.01